Fig. 1 · Structure
Documents & Downloads
2′,2′-Difluorodeoxyuridine
Gemcitabine Metabolite
2′,2′-Difluorodeoxyuridine (dFdU) is a key metabolite of Gemcitabine, primarily targeting the nucleoside incorporation pathway. It exhibits a concentration- and schedule-dependent radiosensitizing effect in vitro, enhancing the efficacy of radiation therapy. Additionally, dFdU facilitates cell cycle arrest during the early S phase and promotes apoptosis in cancer cells, making it a valuable reagent for cancer research and therapeutic investigations.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| CAS Number | 114248-23-6 |
| Applications | Gemcitabine Metabolite |
| Formula | C9H10F2N2O5 |
| Molecular Weight | 264.18 |
| Synonyms | dFdU; 2',2'-Difluoro-2'-deoxyuridine |
| SMILES | O=C(N1)N([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)C=CC1=O |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.